Interface Biologics
Latest round
- Series B
Last raised
- Jan 2015
Total raised
- $7M
Investors
- 5
About Interface Biologics
Founded in 2001, Interface Biologics Inc is based in Toronto, Canada, and focuses on developing cutting-edge biomaterials and drug delivery systems.Interface Biologics Inc develops advanced biomaterials that provide novel drug delivery solutions without the use of polymers. Their flagship technology, Epidel™, enables self-delivery of medications, improving treatment efficacy in conditions like retinal vein occlusion and diabetic macular edema.Interface Biologics Inc generates revenue through strategic partnerships and licensing agreements. Their recent collaboration with AbbVie includes upfront payments, milestone fees, and royalties on net sales for their implant RTC-620, targeting intraocular pressure reduction in glaucoma patients.Looking ahead, Interface Biologics Inc plans to expand its product line, focusing on new drug delivery systems anticipated to launch by 2025. The company aims to enter additional markets in the Asia-Pacific and Latin America regions to meet the rising demand for innovative healthcare solutions.
Who invested in Interface Biologics
5 investors across 2 rounds
See all investors in Interface Biologics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Interface Biologics
Who invested in Interface Biologics?
Interface Biologics has 5 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Interface Biologics raised?
Interface Biologics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Interface Biologics last raise money?
Interface Biologics's most recent round on record is a Series B, in Jan 2015.
What does Interface Biologics do?
Founded in 2001, Interface Biologics Inc is based in Toronto, Canada, and focuses on developing cutting-edge biomaterials and drug delivery systems.
Where is Interface Biologics headquartered?
Interface Biologics is headquartered in Toronto, Canada.
Which VCs invest in companies like Interface Biologics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biopolymers companies at Interface Biologics's stage. Their profiles are linked below.
VCs backing biopolymers startups at Series B
Raising like Interface Biologics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.